Long Ideas - AVEO Pharmaceuticals (NASDAQ:AVEO) announced on Thursday morning that the company will be presenting new data for both of its lead candidates, tivozanib and ficlatuzumab, at … Continue Reading
Read NowLong Ideas - After a Buy rating from theStreet.com yesterday and a presentation Wednesday morning at the UBS Global Life Sciences conference, NPS Pharmaceuticals (NASDAQ:NPSP) gapped up 4% … Continue Reading
Read NowLong Ideas - After Bristol-Myers Squibb (NYSE:BMY) discontinued development of BMS-986094, once a promising nucleotide type drug for hepatitis C (HCV), in August, funds invested in this drug … Continue Reading
Read NowLong Ideas - On Tuesday morning, Navidea Biopharmaceuticals (NASDAQ:NAVB) announced that it commenced enrollment of a Phase II trial for its radiopharmaceutical agent, NAV4694, which is being tested … Continue Reading
Read NowLong Ideas - SciClone Pharmaceuticals (NASDAQ:SCLN) announced Tuesday morning that, as expected, the Chinese government has reduced the list price for Zadaxin. This action has been expected for … Continue Reading
Read NowLong Ideas - Merge Healthcare (NASDAQ:MRGE) fell hard earlier this year when the company announced changes to its business model. In particular, the company moved to offer subscription-based … Continue Reading
Read NowLong Ideas - Vivus (NASDAQ:VVUS) released Monday morning that Qsymia is now commercially available as an aid for weight loss. VVUS had guided for a 4Q 2012 launch … Continue Reading
Read Now